WO2002097119A3 - Verwendung des nachweises der expression von splice-varianten von gen21 für die diagnose und therapie von tumorerkrankungen - Google Patents

Verwendung des nachweises der expression von splice-varianten von gen21 für die diagnose und therapie von tumorerkrankungen Download PDF

Info

Publication number
WO2002097119A3
WO2002097119A3 PCT/DE2002/002001 DE0202001W WO02097119A3 WO 2002097119 A3 WO2002097119 A3 WO 2002097119A3 DE 0202001 W DE0202001 W DE 0202001W WO 02097119 A3 WO02097119 A3 WO 02097119A3
Authority
WO
WIPO (PCT)
Prior art keywords
expression
gene
diagnosis
treatment
splice variants
Prior art date
Application number
PCT/DE2002/002001
Other languages
English (en)
French (fr)
Other versions
WO2002097119A2 (de
Inventor
Dave Brett
Wolfgang Kemmner
Original Assignee
Max Delbrueck Centrum
Dave Brett
Wolfgang Kemmner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum, Dave Brett, Wolfgang Kemmner filed Critical Max Delbrueck Centrum
Priority to AU2002317169A priority Critical patent/AU2002317169A1/en
Publication of WO2002097119A2 publication Critical patent/WO2002097119A2/de
Publication of WO2002097119A3 publication Critical patent/WO2002097119A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Die Erfindung betrifft die Verwendung von Splice-Varianten der Sequenz Gen21 für die Diagnose und Therapie von Tumorerkrankungen. Die mRNA-Expression einer Splice-Variante der Sequenz Gen21 ist in kolorektalen Karzinomen später Stadien reduziert oder nicht vorhanden. Untersuchungen an 100 gut dokumentierten Fällen kolorektaler Karzinome zeigen, dass die Expression der Splice-Variante der Sequenz Gen21 einen prognostischen Faktor für das Überleben solcher Patienten darstellt. Die Aktivierung der Expression dieser Sequenz durch pharmazeutische Mittel ist ebenfalls Gegenstand der Erfindung.
PCT/DE2002/002001 2001-05-31 2002-05-30 Verwendung des nachweises der expression von splice-varianten von gen21 für die diagnose und therapie von tumorerkrankungen WO2002097119A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002317169A AU2002317169A1 (en) 2001-05-31 2002-05-30 Use of the indication of the expression of splice variants of gene 21 for the diagnosis and treatment of tumour diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10126472.0 2001-05-31
DE2001126472 DE10126472A1 (de) 2001-05-31 2001-05-31 Verwendung des Nachweises der Expression von Splice-Varianten von Gen21 für die Diagnose und Therapie von Tumorerkrankungen

Publications (2)

Publication Number Publication Date
WO2002097119A2 WO2002097119A2 (de) 2002-12-05
WO2002097119A3 true WO2002097119A3 (de) 2003-05-30

Family

ID=7686732

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2002/002001 WO2002097119A2 (de) 2001-05-31 2002-05-30 Verwendung des nachweises der expression von splice-varianten von gen21 für die diagnose und therapie von tumorerkrankungen

Country Status (3)

Country Link
AU (1) AU2002317169A1 (de)
DE (1) DE10126472A1 (de)
WO (1) WO2002097119A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003294250A1 (en) * 2002-11-12 2004-06-03 Wyeth A novel pth responsive gene

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1991, ZEEH A ET AL: "THE PRODUCT OF THE SPLIT SUNY GENE OF BACTERIOPHAGE T4 IS A PROCESSED PROTEIN", XP002231566, Database accession no. PREV199293027928 *
DATABASE EBI [online] XP002231567, Database accession no. BC002791.1 *
DATABASE EBI [online] XP002231568, Database accession no. AF040707 *
DATABASE EBI [online] XP002231569, Database accession no. AAX39651 *
JOURNAL OF BACTERIOLOGY, vol. 173, no. 21, 1991, pages 6980 - 6985, ISSN: 0021-9193 *
LERMAN MICHAEL I ET AL: "The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: Identification and evaluation of the resident candidate tumor suppressor genes.", CANCER RESEARCH, vol. 60, no. 21, 1 November 2000 (2000-11-01), pages 6116 - 6133, XP002231565, ISSN: 0008-5472 *
STOSS ET AL, GENE THER MOL BIOL, vol. 5, December 2000 (2000-12-01), pages 9 - 30, XP002231564, Retrieved from the Internet <URL:stamms-lab.net/pdfs/stossGT.pdf> [retrieved on 20030218] *

Also Published As

Publication number Publication date
AU2002317169A1 (en) 2002-12-09
WO2002097119A2 (de) 2002-12-05
DE10126472A1 (de) 2002-12-05

Similar Documents

Publication Publication Date Title
WO2002087555A3 (en) Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
AU2003239531A1 (en) Protein cages for the delivery of medical imaging and therapy
AU7031500A (en) Therapeutic quinazoline compounds
WO2002074337A8 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
AU2002251841A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2002311909A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2002218770A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
HUP0001014A2 (hu) Gasztrointesztinális lipáz inhibitorok felhasználása
NO20013958L (no) Legemiddel for behandling av höyt blodtrykk
AU2002359330A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
DK1353948T3 (da) Oplöselige biologiske analoge til bata-amyloidpeptid
AU6425800A (en) Agents for the diagnosis, prognosis and treatment of malignant diseases
AU2001259062A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
GB9907571D0 (en) Compounds
AU2002313726A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2002097119A3 (de) Verwendung des nachweises der expression von splice-varianten von gen21 für die diagnose und therapie von tumorerkrankungen
EP1051976A3 (de) Verwendung von Bisphosphonaten zur Behandlung von Osteogenese Imperfecta
AU2001273149A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2001232053A1 (en) System for the extracorporeal treatment of blood
HUP0402061A2 (hu) Rosszindulatú daganatok kezelésére alkalmas, egy biszfoszfonát, egy COX-2 inhibitor és egy taxol kombinációját tartalmazó gyógyszerkészítmények
AU2002306600A1 (en) Sperm protein 17 for the diagnosis and treatment of cancer
AU2002365104A1 (en) Method for the diagnosis of breast cancer diseases, associated peptides and the uses thereof
AU2002214950A1 (en) Determination of the ability of patients to respond to tumour treatment
NO981320L (no) Oral anvendelse av (+)-O-demetyltramadol som smertemiddel
PL376407A1 (en) Medicament containing disorazoles and derivatives thereof for the treatment of benign and malignant tumoral diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP